Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CYP2C19 polymorphism and proton pump inhibitors.

Ulrich Klotz1, Matthias Schwab, Gerhard Treiber

  • 1Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstr. 112, D-70376 Stuttgart, Germany. ulrich.klotz@ikp-stuttgart.de

Basic & Clinical Pharmacology & Toxicology
|July 13, 2004
PubMed
Summary

Proton pump inhibitors

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[How to manage polypharmacia?]

Deutsche medizinische Wochenschrift (1946)·2021
Same author

Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions.

Pharmaceutics·2020
Same author

Physiologically Based Precision Dosing Approach for Drug-Drug-Gene Interactions: A Simvastatin Network Analysis.

Clinical pharmacology and therapeutics·2020
Same author

Metabolic Drug Response Phenotyping in Colorectal Cancer Organoids by LC-QTOF-MS.

Metabolites·2020
Same author

Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper.

Oncology research and treatment·2020
Same author

Stereoselective quantification of phase 1 and 2 metabolites of clomiphene in human plasma and urine.

Talanta·2020

Area of Science:

  • Pharmacogenomics
  • Drug Metabolism
  • Gastroenterology

Background:

  • Proton pump inhibitors (PPIs) are metabolized by the polymorphic CYP2C19 enzyme.
  • Three CYP2C19 phenotypes exist: extensive, poor, and heterozygous extensive metabolizers.
  • Metabolism variations significantly impact PPI systemic exposure and efficacy.

Purpose of the Study:

  • To investigate the influence of CYP2C19 genetic variations on proton pump inhibitor pharmacokinetics and pharmacodynamics.
  • To correlate CYP2C19 phenotypes with clinical outcomes in Helicobacter pylori eradication and gastro-oesophageal reflux disease.

Main Methods:

  • Analysis of proton pump inhibitor pharmacokinetics (AUC) across different CYP2C19 metabolizer phenotypes.
  • Evaluation of pharmacodynamic responses, including intragastric pH elevation.
  • Correlation of CYP2C19 genotype with clinical efficacy in H. pylori eradication and GERD healing.

Main Results:

  • Systemic exposure (AUC) to PPIs is 5-12 times higher in poor metabolizers than extensive metabolizers.
  • Higher intragastric pH levels are observed in poor and heterozygous extensive metabolizers.
  • Significantly higher H. pylori eradication rates and improved GERD healing rates are noted in poor and heterozygous extensive metabolizers.

Conclusions:

  • CYP2C19 genotype significantly influences proton pump inhibitor efficacy.
  • Initial genotyping for CYP2C19 can guide personalized dosing strategies.
  • Higher PPI dosages in extensive metabolizers and genotyping for poor/heterozygous extensive metabolizers may enhance clinical outcomes.

Related Experiment Videos